Data as of Sep 21, 2026 · Based on 3,332,371 AI responses across 10,526 prompts · See how Parse measures this
No contexts measured yet.
ClearNote Health develops blood-based early cancer detection tests to identify signals of cancer in the blood before symptoms, enabling earlier treatment for high-risk patients. The company offers Avantect Pancreatic Cancer Test, Avantect Ovarian Cancer Test, and Avantect MCD Test for early detection of pancreatic and ovarian cancers, along with the Virtuoso Epigenomics Platform that measures dynamic disease biology from a blood draw. The Virtuoso platform is for research use only and not diagnostic, and the Avantect tests are early detection tests that are not FDA-cleared and do not by themselves diagnose cancer.
Parse Score